Several analysts have recently updated their ratings and price targets for Agios Pharmaceuticals (NASDAQ: AGIO):

  • 5/31/2019 – Agios Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 5/23/2019 – Agios Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Goldman Sachs Group Inc. They now have a $55.00 price target on the stock.
  • 5/16/2019 – Agios Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 5/16/2019 – Agios Pharmaceuticals had its price target raised by analysts at Royal Bank of Canada to $90.00.
  • 5/9/2019 – Agios Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 5/3/2019 – Agios Pharmaceuticals had its price target lowered by analysts at Piper Jaffray Companies from $100.00 to $85.00. They now have an “overweight” rating on the stock.
  • 4/25/2019 – Agios Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Agios' first wholly owned precision medicine, Tibsovo, was approved by the FDA last July 2018 for treating R/R AML. The drug generated strong sales in the reported quarter. Tibsovo’s label expansion studies also look promising with the FDA recently granting a priority review in first-line setting. Agios’ progress with pipeline candidates, namely AG-348 and AG-881, has been quite impressive too. We are also optimistic about Agios' collaboration with Celgene as it provides the company with regular funds and royalties from Idhifa sales. However, Agios’ heavy dependence on partner Celgene for royalties remains an overhang. Stiff competition from big pharma companies is another matter of concern for the company. Shares have outperformed the industry in the year so far. Loss estimates have widened ahead of Q1 earnings. Agios has a positive record of earnings surprises in the recent quarters.”
  • 4/24/2019 – Agios Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/18/2019 – Agios Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 4/13/2019 – Agios Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of AGIO opened at $49.26 on Wednesday. Agios Pharmaceuticals Inc has a 12 month low of $41.63 and a 12 month high of $99.82. The firm has a market cap of $2.81 billion, a PE ratio of -8.17 and a beta of 2.33. The company has a current ratio of 6.89, a quick ratio of 6.86 and a debt-to-equity ratio of 0.11.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.74) by $0.15. Agios Pharmaceuticals had a negative net margin of 300.63% and a negative return on equity of 48.19%. The company had revenue of $30.20 million for the quarter, compared to analyst estimates of $22.69 million. During the same quarter in the prior year, the business posted ($1.63) EPS. Agios Pharmaceuticals’s quarterly revenue was up 243.2% on a year-over-year basis. Equities research analysts forecast that Agios Pharmaceuticals Inc will post -6.76 earnings per share for the current fiscal year.

In other news, insider Scott Biller sold 3,000 shares of the stock in a transaction on Friday, April 5th. The shares were sold at an average price of $67.71, for a total transaction of $203,130.00. Following the transaction, the insider now owns 29,511 shares in the company, valued at approximately $1,998,189.81. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Christopher Bowden sold 10,000 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $64.16, for a total transaction of $641,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,000 shares of company stock worth $1,510,430. 3.16% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC increased its stake in shares of Agios Pharmaceuticals by 0.4% during the 1st quarter. FMR LLC now owns 8,759,313 shares of the biopharmaceutical company’s stock worth $590,728,000 after purchasing an additional 32,512 shares during the last quarter. BlackRock Inc. increased its stake in shares of Agios Pharmaceuticals by 0.3% during the 1st quarter. BlackRock Inc. now owns 3,334,365 shares of the biopharmaceutical company’s stock worth $224,869,000 after purchasing an additional 9,886 shares during the last quarter. BB Biotech AG increased its stake in shares of Agios Pharmaceuticals by 30.9% during the 4th quarter. BB Biotech AG now owns 2,878,134 shares of the biopharmaceutical company’s stock worth $132,711,000 after purchasing an additional 680,203 shares during the last quarter. First Trust Advisors LP increased its stake in shares of Agios Pharmaceuticals by 31.4% during the 1st quarter. First Trust Advisors LP now owns 1,774,158 shares of the biopharmaceutical company’s stock worth $119,649,000 after purchasing an additional 423,931 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Agios Pharmaceuticals by 24.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,636,073 shares of the biopharmaceutical company’s stock valued at $110,337,000 after buying an additional 320,626 shares during the last quarter.

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Read More: Why Invest in Dividend Achievers?

Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.